RDIF and partners invest in Alium pharmaceutical holding
Moscow, July 9, 2019 - A consortium of investors, including the Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund), the Russia-China Investment Fund (RCIF, established by RDIF and China Investment Corporation), and leading Middle Eastern funds, have announced a 28% stake in Alium pharmaceutical holding.
Alium holding is created by a merger between the pharmaceutical companies Obolenskoe and Binnopharm. Following the merger, Alium is among the top-10 Russian pharmaceutical companies in the sector, with a diversified portfolio of over 200 drugs. The production capacity of the merged company is supplied by four pharmaceutical production units in Moscow and the Moscow region.
Kirill Dmitriev, CEO of the Russian Direct Investment Fund (RDIF), said:
“We have completed an important stage in the creation of Alium holding, whose products will meet the market’s demands for modern and effective medicines. The Fund, together with its partners, plans to consider further such attractive investment projects in the pharmaceutical industry”.
Russian Direct Investment Fund (RDIF) is Russia's sovereign wealth fund established in 2011 to make equity co-investments, primarily in Russia, alongside reputable international financial and strategic investors. RDIF acts as a catalyst for direct investment in the Russian economy. RDIF’s management company is based in Moscow. Currently, RDIF has experience of the successful joint implementation of more than 70 projects with foreign partners totaling more than RUB 1.5tn and covering 95% of the regions of the Russian Federation. RDIF portfolio companies employ more than 800,000 people and generate revenues which equate to more than 6% of Russia’s GDP. RDIF established joint strategic partnerships with leading international co-investors from more than 15 countries that total more than $40bn. Further information can be found at www.rdif.ru
For additional information contact:
Arseniy Palagin Maria Shiryaevskaya / Andrew Leach
Russian Direct Investment Fund Hudson Sandler
Press Secretary Tel: +44 (0) 20 7796 4133
Tel: +7 495 644 34 14, ext. 2395
Mobile: +7 916 110 31 41